SS Innovations International Executive Compensation
SS Innovations International appointed Gary G. Lo as Chief Financial Officer and promoted Dr. Vishwa Srivastava to President. Mr. Lo's compensation includes a $400,000 base salary, a 50% target bonus, and 500,000 stock options with an exercise price of $2.11 per share.
SS Innovations International showcased its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console during successful long-distance telesurgeries at major medical conferences in Barcelona and New Delhi. The demonstrations included a cardiac procedure performed remotely from 7,500 miles away, highlighting the system's ultra-low latency and remote surgical capabilities.
SS Innovations International submitted its response to the FDA's request for additional information regarding its 510(k) application for the SSi Mantra surgical robotic system. The response includes final data from expanded human clinical and human factors validation studies, with a final FDA review decision anticipated in the first quarter of 2027.
SS Innovations International $21M Debt Financing with institutional investor
SS Innovations International entered into a Securities Purchase Agreement with an institutional investor for the issuance of a secured convertible promissory note in the principal amount of $21.025 million. The note carries an 8.75% interest rate and is secured by the company's intellectual property and other assets, excluding its Indian operating subsidiary. Proceeds will be used for general corporate purposes, and the note is convertible into common shares at a discount to the market price.
SS Innovations International Investor Presentation
SS Innovations International, Inc. (SSII) filed an updated October 2026 Company Presentation to be used in communications with shareholders and the investment community. The presentation highlights the company's proprietary surgical robotic system, the SSi Mantra 3, and its vision for affordable surgical robotic solutions.